BCL-2, in combination with MVP and IGF-1R expression, improves prediction of clinical outcome in complete response cervical carcinoma patients treated by radiochemotherapy

详细信息    查看全文

• 作者：Luis Alberto Henr&#xed ; quez-Herná ; ndez^a ; ^b ; ^c ; ^{lhenriquez@dcc.ulpgc.es"" rel=""nofollow} ; Marta Lloret^a ; ^b ; ^c ; Beatriz Pinar^a ; ^b ; ^c ; Elisa Bordó ; n^a ; ^b ; ^c ; Agust&#xed ; n Rey^d ; Amina Lubrano^e ; Pedro Carlos Lara^a ; ^b ; ^c
• 关键词：BCL-2 ; Ku70/80 ; Major vault protein (MVP) ; IGF-1R ; Cervical cancer
• 刊名：Gynecologic Oncology
• 出版年：2011
• 出版时间：September 2011
• 年：2011
• 卷：122
• 期：3
• 页码：585-589
• 全文大小：333 K

文摘

Objectives

To investigate whether BCL-2 expression would improve MVP/IGF-1R prediction of clinical outcome in cervix carcinoma patients treated by radiochemotherapy, and suggest possible mechanisms behind this effect.

Methods

Fifty consecutive patients, who achieved complete response to treatment, from a whole series of 60 cases suffering from non-metastatic localized cervical carcinoma, were prospectively included in this study from July 1999 to December 2003. Follow-up was closed in January 2011. All patients received pelvic radiation (45–64.80 Gy in 1.8–2 Gy fractions) with concomitant cisplatin at 40 mg/m2/week doses followed by brachytherapy. Oncoprotein expression was studied by immunohistochemistry in paraffin-embedded tumour tissue.

Results

No relation was found between BCL-2 and clinicopathological variables. High MVP/IGF-1R/BCL-2 tumour expression was strongly related to poor local and regional disease-free survival (P < 0.0001), distant disease-free survival (P = 0.010), disease-free survival (P < 0.0001), and cause-specific survival (P < 0.0001). NHEJ repair protein Ku70/80 expression was significantly repressed in tumours overexpressing all three oncoproteins (P = 0.047). No differences were observed in proliferation (Ki67 expression) or P53 alteration.

Conclusions

BCL-2, MVP, and IGF-1R overexpression were related to poorer clinical outcome in cervical cancer patients who achieved clinical complete response to radiochemotherapy. The NHEJ repair protein Ku70/80 expression could be involved in the regulation of these oncoproteins.